The direct nucleic acid repair dioxygenase FTO is an enzyme that demethylates N(6)-methyladenosine (m(6)A) residues in mRNA in vitro and inside cells. FTO is the first RNA demethylase discovered that also serves a major regulatory function in mammals. Together with structure-based virtual screening and biochemical analyses, we report the first identification of several small-molecule inhibitors of human FTO demethylase. The most potent compound, the natural product rhein, which is neither a structural mimic of 2-oxoglutarate nor a chelator of metal ion, competitively binds to the FTO active site in vitro. Rhein also exhibits good inhibitory activity on m(6)A demethylation inside cells. These studies shed light on the development of powerful probes and new therapies for use in RNA biology and drug discovery.

We surveyed influenza activity in a live poultry market in Central China for 16 months, isolating viruses from 1% of 6360 fecal samples. We obtained multiple H3N6, H9N2, H2N9, H3N3, and H4N6 isolates and single H1N1 and H3N2 isolates. Two distinct H3 molecules were identified; other hemagglutinin subtypes were phylogenetically homogeneous. The H3N6 viruses (9 genotypes) and H9N2 viruses (4 genotypes) were genetically heterogeneous, whereas the H2N9, H3N3 and H4N6 viruses had single genotypes. Thirteen representative viruses were tested for their ability to replicate in quail and chickens. All tested viruses replicated in the respiratory tract of quail. Only nine of the viruses were shed in detectable levels in infected chickens, and four of these were detected in less than 50% of infected birds. A single H4N6 isolate caused disease and systemic spread in chickens. These findings show that quail are broadly susceptible to different subtypes of influenza A virus.

Adjuvants have been of great interest to vaccine formulation as immune-stimulators. Prior to the recent research in the field of immune stimulation, conventional adjuvants utilized for aluminum-based vaccinations dominated the adjuvant market. However, these conventional adjuvants have demonstrated obvious defects, including poor protective efficiency and potential side effects, which hindered their widespread circulation. Outer membrane vesicles (OMVs) naturally exist in gram-negative bacteria and are capable of engaging innate and adaptive immunity and possess intrinsic adjuvant capacity. They have shown tremendous potential for adjuvant application and have recently been successfully applied in various vaccine platforms. Adjuvants could be highly effective with the introduction of OMVs, providing complete immunity and with the benefits of low toxicity; further, OMVs might also be designed as an advanced mucosal delivery vehicle for use as a vaccine carrier. In this review, we discuss adjuvant development, and provide an overview of novel OMV adjuvants and delivery vehicles. We also suggest future directions for adjuvant research. Overall, we believe that OMV adjuvants would find high value in vaccine formulation in the future.

No abstract